Receptor binding profile and anxiolytic‐type activity of deramciclane (EGIS‐3886) in animal models

@article{Gacslyi1997ReceptorBP,
  title={Receptor binding profile and anxiolytic‐type activity of deramciclane (EGIS‐3886) in animal models},
  author={I. Gacs{\'a}lyi and {\'E}. Schmidt and I. Gyertyán and E. Vasar and A. Lang and A. Haapalinna and M. Fekete and J. Hietala and E. Syv{\"a}lahti and P. Tuomainen and P. M{\"a}nnist{\"o}},
  journal={Drug Development Research},
  year={1997},
  volume={40}
}
The present series of experiments was done to characterize the properties of deramciclane, a new antiserotonergic drug, in both receptor binding studies in vitro and in a number of anxiolytic, antidepressant, and antidopaminergic tests in rodents. A striking property of deramciclane was its high affinity to both 5‐HT2A and 5‐HT2C receptors (Ki = 8.7–27 nM/l). Deramciclane had also a moderate affinity to dopamine D2 and sigma receptors but did not interact with any of the adrenergic receptors. 
Comparison of deramciclane to benzodiazepine agonists in behavioural activity of mice and in alcohol drinking of alcohol-preferring rats
TLDR
Deramciclane appears to be a safe and well-tolerated drug and it is suggested that it might be useful in the treatment of anxiety in alcoholics. Expand
Role of CCK in anti-exploratory action of paroxetine, 5-HT reuptake inhibitor.
TLDR
It is likely that the anti-exploratory action of a low dose of paroxetine is not related to the increase in anxiety, but rather to the reduction of exploratory drive, and evidence exists that this effect of paroxin is mediated via the activation of CCK-ergic transmission. Expand
Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.
TLDR
There is at least a 5-fold margin between the anxiolytic and neuroleptic doses of deramciclane in the rat, particularly in mesolimbic regions. Expand
Serotonergic targets in depression.
Serotonin reuptake inhibitors have proved to be a very effective treatment for depression and have strengthened the hypothesis that impaired 5-hydroxytryptamine (5-HT) neurotransmission mayExpand
Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration – a positron emission tomography study
TLDR
Deramciclane penetrates the blood-brain barrier in humans and binds to the 5-HT2A receptors in the frontal cortex in a saturable manner in vivo, indicating a non-5- HT2A receptor binding component of this radioligand in frontal cortex. Expand
Selective binding interactions of deramciclane to the genetic variants of human alpha(1)-acid glycoprotein.
TLDR
The binding interactions found prove that AGP can simultaneously accommodate different ligand molecules, and even weakly bound ligands can provoke unexpected allosteric protein binding interactions. Expand
Oral, Intraperitoneal and Intravenous Pharmacokinetics of Deramciclane and its N‐desmethyl Metabolite in the Rat
TLDR
The pharmacokinetic properties of deramciclane fumarate (EGIS‐3886), a new potential anxiolitic agent, and its N‐desmethyl metabolite have been investigated in Wistar rats after it was administered orally, intraperitoneally or intravenously. Expand
Therapeutic potential of serotonin antagonists in depressive disorders
TLDR
Here, the profiles of novel serotonin antagonists currently in preclinical development are reviewed and their therapeutic potential is assessed. Expand
Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?
  • G. Griebel
  • Biology, Medicine
  • Pharmacology & therapeutics
  • 1999
TLDR
Findings suggest that compounds targeting specific neuropeptide receptors may become an alternative to benzodiazepines for the treatment of anxiety disorders. Expand
8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze
TLDR
The 5-HT reuptake inhibitor, paroxetine, at a low dose (0.5 mg/kg) induces an anxiogenic-like action in handling adapted rats, which probably supports a role of both pre- and postsynaptic 5- HT-ergic mechanisms in the anxiogensic action of paroxETine. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 65 REFERENCES
The potential anxiolytic activity of GR38032F, a 5‐HT3‐receptor antagonist
TLDR
It is concluded that GR38032F is potentially a very potent anxiolytic agent without sedative, anticonvulsant or hypnotic activity. Expand
Anxiolytic potential of 5-HT3 receptor antagonists.
TLDR
The preclinical data indicates the 5-HT3 receptor antagonists as novel anxiolytics of the future, and there is new clinical work in support of this suggestion. Expand
Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation
TLDR
Data indicate that deramciclane is a 5- HT2C receptor inverse agonist and occupies 5-HT2C receptors during treatment, and that chronic treatment with deramCiclane does not lead to5-HT 2C receptor down-regulation. Expand
Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist.
TLDR
SR 57746A was inactive or only very weakly active in a series of tests typical of benzodiazepine-like activity, including antagonism of pentetrazol-induced seizures, reduction of muscle tone and locomotor activity, impairment of motor co-ordination, and potentiation of the effects of centrally-acting sedative-hypnotics. Expand
Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder
TLDR
This multicenter trial of CGS-15040A in patients with generalized anxiety disorder demonstrated clinical anxiolytic effects consistent with established preclinical effects, and the dose-response relationship was nonlinear. Expand
Recent developments in 5HT-related pharmacology of animal models of anxiety
  • C. Gardner
  • Medicine, Psychology
  • Pharmacology Biochemistry and Behavior
  • 1986
TLDR
Preliminary clinical reports indicate qualitatively different anxiolytic activity from that of benzodiazepines, but further studies are necessary before associating modulation of central 5HT systems with anxioselective activity, either in animal models or patients. Expand
Behavioral pharmacology of antagonists at 5-HT2/5-HT1C receptors
TLDR
Behavioral procedures used to characterize 5-HT2 antagonist properties of compounds and behavioral models of clinical activity in which 5- HT2 antagonists have been reported to be active are examined. Expand
Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists.
TLDR
It is demonstrated that clozapine and one of its major metabolites in man, N-desmethylclozapines, are potent 5-HT1C receptor antagonists. Expand
Evidence for a role of haloperidol‐sensitive σ‐'opiate' receptors in the motor effects of antipsychotic drugs
TLDR
Haloperidol exhibits a high affinity for a subclass of σ-"opiate" binding sites which have a unique anatomic distribution and a unique drug selectivity pattern, which suggest that σ-binding sites represent biologically functional receptors that are active in the neural control of movement. Expand
Anxiolytic effects of CCK-B antagonists
TLDR
It is concluded that CCK-B receptors are involved in aversive-anxiety responding and that CCk-B receptor antagonists may provide a novel and improved approach to the treatment of anxiety and withdrawal from drugs of abuse. Expand
...
1
2
3
4
5
...